Form 8-K

8-K — Aditxt, Inc.

Accession: 0001213900-26-063165

Filed: 2026-06-01

Period: 2026-05-29

CIK: 0001726711

SIC: 2834 (PHARMACEUTICAL PREPARATIONS)

Item: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

Item: Regulation FD Disclosure

Item: Financial Statements and Exhibits

Documents

8-K — ea0292902-8k_aditxt.htm (Primary)

EX-99.1 — PRESS RELEASE OF ADITXT, INC., DATED JUNE 1, 2026 (ea029290201ex99-1.htm)

XML — IDEA: XBRL DOCUMENT (R1.htm)

8-K — CURRENT REPORT

8-K (Primary)

Filename: ea0292902-8k_aditxt.htm · Sequence: 1

false

0001726711

2026-05-29

iso4217:USD

xbrli:shares

iso4217:USD

xbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities

Exchange Act of 1934

Date of Report (Date of earliest event reported):

May 29, 2026

ADITXT, INC.

(Exact name of registrant as specified in its

charter)

Delaware

(State or other jurisdiction of incorporation)

001-39336

82-3204328

(Commission File Number)

(I.R.S. Employer Identification No.)

2569 Wyandotte Street, Suite 101

Mountain View, California 94043

(Address of principal executive offices, including

zip code)

(650) 870-1200

(Registrant’s telephone number, including

area code)

N/A

(Former name or former address, if changed since

last report)

Check the appropriate box below if the Form 8-K

filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class

Trading Symbol(s)

Name of each exchange on which registered

Common Stock, par value $0.001 per share

ADTX

The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant

is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities

Exchange Act of 1934 (17 CFR §240.12b-2).

Emerging growth company ☐

If an emerging growth company, indicate by check

mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting

standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 5.02. Departure of Directors or Certain Officers; Election

of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

Resignation of Chief Executive Officer and Director – Amro

Albanna

On May 29, 2026, Amro Albanna notified the Company of his decision

to resign as Chief Executive Officer of Aditxt, Inc. (the “Company”), and on May 30, 2026, Mr. Albanna resigned as a member

of the Company’s Board of Directors (the “Board”), effective immediately. On May 31, 2026, the Board accepted Mr. Albanna’s

resignation as Chief Executive Officer, effective as of such date. Mr. Albanna’s resignation as a director was not the result of

any disagreement with the Company on any matter relating to the Company’s operations, policies, or practices.

Resignation of Director – Shahrokh Shabahang

On May 31, 2026, Shahrokh Shabahang resigned as a member of the Board,

effective immediately. Dr. Shabahang’s resignation was not the result of any disagreement with the Company on any matter relating

to the Company’s operations, policies, or practices. Dr. Shabahang continues to serve as the Company’s Chief Innovation Officer.

Resignation of Chief Operating Officer – Rowena Albanna

On May 31, 2026, Rowena Albanna notified the Company of her decision

to resign as Chief Operating Officer of the Company, effective June 5, 2026.

Appointment of Interim Chief Executive Officer – Jeffrey

M. Busch

On May 31, 2026, the Board appointed Jeffrey M. Busch, age 68, to serve

as Interim Chief Executive Officer of the Company, effective as of such date.

Mr. Busch has served as Chief Executive Officer of Ignite Proteomics

LLC, a wholly owned subsidiary of the Company, since March 2026. From June 2014 to June 2025, Mr. Busch served as Founder, Chairman and

Chief Executive Officer of Global Medical REIT Inc. (NYSE: GMRE), a healthcare real estate company that he founded and took public on

the New York Stock Exchange. Since 1999, Mr. Busch has also served as Founder, President and Chief Executive Officer of Safe Blood International

Foundation, a global public health organization. Over the course of more than three decades, Mr. Busch has held director and senior executive

roles across a number of biotechnology, diagnostics, and medical technology companies, and previously held two U.S. presidential appointments,

including service as a United States Delegate to the United Nations in Geneva and as Assistant to the Secretary of the U.S. Department

of Housing and Urban Development. Mr. Busch holds a J.D. from Emory University School of Law and an M.P.A. and a B.S. in Business from

New York University.

There are no arrangements or understandings between Mr. Busch and any

other person pursuant to which he was appointed as Interim Chief Executive Officer. There are no family relationships between Mr. Busch

and any director or executive officer of the Company. There are no transactions, or proposed transactions, to which the Company is or

was a participant and in which Mr. Busch has a material interest that would be required to be disclosed pursuant to Item 404(a) of Regulation

S-K.

In connection with his appointment as Interim Chief Executive Officer,

the Company intends to enter into an interim employment arrangement with Mr. Busch providing for an annual base salary of $500,000. The

material terms of such arrangement had not been finalized as of the date of this Current Report on Form 8-K. The Company will file an

amendment to this Current Report on Form 8-K containing the information required by Item 5.02(c)(3) within four business days after the

material terms of Mr. Busch’s compensatory arrangement are determined.

Appointment of Chairman of the Board – Brian Brady

On May 31, 2026, the Board appointed Brian Brady, an independent director

of the Company, to serve as non-executive Chairman of the Board, effective as of such date.

Item 7.01. Regulation FD Disclosure.

On June 1, 2026, the Company issued a press release

announcing the matters described in Item 5.02 of this Current Report on Form 8-K. A copy of the press release is furnished as

Exhibit 99.1 hereto.

The information furnished under this Item 7.01, including Exhibit 99.1,

shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange

Act”), or otherwise subject to the liabilities of that section, and shall not be deemed incorporated by reference into any filing

under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

Exhibit No.

Description

99.1

Press Release of Aditxt, Inc., dated June 1, 2026 (furnished herewith)

104

Cover Page Interactive Data File (embedded within the XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities

Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

ADITXT, INC.

Date: June 1, 2026

By:

/s/ Thomas

Farley

Name:

Thomas Farley

Title:

Chief Financial Officer

EX-99.1 — PRESS RELEASE OF ADITXT, INC., DATED JUNE 1, 2026

EX-99.1

Filename: ea029290201ex99-1.htm · Sequence: 2

Exhibit 99.1

ADITXT,

INC. (NASDAQ: ADTX)

PRESS RELEASE

FOR IMMEDIATE RELEASE

Aditxt,

Inc. Appoints Jeffrey M. Busch as Interim Chief Executive Officer; Founder and Former CEO of $1B NYSE Enterprise Which Delivered

~8.5% Dividends to Shareholders

Seasoned executive who founded and built a NYSE-listed healthcare

real estate company to over $1 billion in enterprise value — delivering an average dividend yield of approximately 8.5% to shareholders

— brings capital markets depth, healthcare sector expertise, and commercial discipline to lead Aditxt’s next chapter of revenue-driven

growth.

Mountain View, California — June 1, 2026

— Aditxt, Inc. (Nasdaq: ADTX)(“Aditxt” or the “Company”), a life sciences platform company

accelerating promising health innovations, today announced the appointment of Jeffrey M. Busch as Interim Chief Executive Officer of

Aditxt, Inc., effective May 31, 2026. Mr. Busch, who has served as Chief Executive Officer of Aditxt’s CLIA-certified

precision oncology diagnostics subsidiary Ignite Proteomics, LLC (“Ignite”) since March 2026, will now lead the full

Aditxt enterprise as it executes an accelerated commercialization strategy centered on Ignite’s precision oncology diagnostics

platform. Mr. Busch simultaneously continues in his role as CEO of Ignite.

The Board of Directors expressed its deep appreciation

for the contributions of outgoing CEO Amro Albanna, who resigned as CEO, from the Company’s Board and from all positions with the

Company’s subsidiaries. Mr. Albanna co-founded Aditxt and led the Company through its founding vision, public listing, and acquisition

strategy, including the addition of Ignite to the Aditxt portfolio. Mr. Albanna’s scientific conviction and entrepreneurial persistence

established the foundation upon which the Company’s next chapter will be built. The Board wishes him well in his future endeavors.

“Jeff

brings exactly the combination of skills this moment requires: public company leadership, capital markets credibility, deep healthcare-sector

expertise, and a track record of building shareholder value in a regulated, mission-driven environment. We are confident that under his

leadership, Aditxt will accelerate the commercial trajectory of Ignite Proteomics while ensuring that every decision reflects our responsibility

to patients, partners, employees, and investors alike.”

— Brian Brady, Chairman of the Board, Aditxt,

Inc.

About Jeffrey M. Busch

Mr. Busch is the Founder, Chairman, and former

Chief Executive Officer of Global Medical REIT, Inc. (NYSE: GMRE), now Chiron Real Estate, Inc. (NYSE: XRN), a NYSE-listed net-lease healthcare

real estate investment trust that he founded and built to over $1 billion in enterprise value. Throughout his tenure as CEO, Mr. Busch

maintained a consistent and disciplined dividend program, delivering an average annual dividend yield of approximately 8.5% to common

shareholders — a track record that reflects both his commitment to capital stewardship and his ability to build institutional-grade

infrastructure within a regulated, healthcare-focused business environment.

A graduate of the New York University Stern School

of Business with a Bachelor of Science in Business, Mr. Busch also holds a Master of Public Administration specializing in health policy

from New York University and a Juris Doctor from Emory University. His academic foundation spans law, business, and health policy —

a rare combination that has informed both his regulatory approach and his commercial strategy throughout a career at the intersection

of healthcare and capital markets.

Earlier in his career, Mr. Busch served as a congressional

aide before being appointed by two United States Presidents to serve in their administrations, including as a United States Delegate to

the United Nations in Geneva. Since 2001, he has served as President of the Safe Blood International Foundation, overseeing the establishment

of medical facilities in 35 developing nations — programs funded by the CDC, USAID, ExxonMobil, and the Gates Foundation. This global

health mission underscores a career defined not only by financial performance, but by a genuine commitment to expanding access to life-saving

medical care.

“Aditxt and Ignite sit at

one of the most important intersections in modern medicine — precision diagnostics and patient-centered oncology care. With approximately

40% of cancer drugs not working for the patients they are prescribed to, the clinical imperative behind what Ignite does could not be

more clear. My focus will be on translating that clinical imperative into a commercially excellent, financially disciplined, and patient-first

organization. We have a Medicare-reimbursed platform, growing clinical validation, established research partnerships, and a large and

expanding addressable market. The work ahead is to build on that foundation with urgency and accountability — to our patients, to

our people, and to our shareholders.”

— Jeffrey M. Busch, Interim Chief

Executive Officer, Aditxt, Inc.

Strategic Priorities Under New

Leadership

Under Mr. Busch’s leadership, Aditxt intends to

advance the following core strategic priorities:

● Patients

First, Always. Every strategic and operational decision will be evaluated against a single standard: “does it serve patients

and improve their lives?”. This commitment is non-negotiable and will govern the Company’s culture, capital allocation, and commercial

behavior.

● Revenue-Driven

Innovation. Aditxt will pursue clinical innovation and commercial performance with equal discipline — deepening the clinical

evidence base that supports Ignite’s RPPA platform while simultaneously building the revenue infrastructure necessary to fund continued

R&D and sustain the Company’s mission long-term.

● Responsibility

to All Stakeholders. The Company will operate with full transparency and financial discipline — meeting its obligations to

employees, clinical partners, vendors, and shareholders, and building an organization worthy of the trust placed in it by every constituency

it serves.

● Capital

Market Engagement. Drawing on Mr. Busch’s experience building and sustaining a NYSE-listed public company, Aditxt will pursue proactive

investor relations, responsible capital stewardship, and strategic partnership development to support the Company’s growth trajectory

and enhance long-term shareholder value.

About Aditxt, Inc.

Aditxt, Inc. (Nasdaq: ADTX) is a life sciences

platform company focused on accelerating promising health innovations. Through its subsidiary Ignite Proteomics, Aditxt operates a CLIA-certified

precision oncology diagnostics laboratory that uses Reverse Phase Protein Array (RPPA) technology to help physicians identify the most

effective cancer treatment for each individual patient. Ignite holds a Medicare PLA code and has established clinical collaborations with

leading cancer research institutions including Dana-Farber Cancer Institute and Vanderbilt University Medical Center.

About Ignite Proteomics

Ignite Proteomics is a CLIA-certified precision

oncology diagnostics company utilizing proprietary Reverse Phase Protein Array (RPPA) technology to deliver functional protein-level analysis

that guides cancer treatment selection. With Medicare reimbursement established through a dedicated PLA code and growing clinical validation

across multiple cancer types, Ignite is positioned to address one of oncology’s most persistent challenges: ensuring that the right patient

receives the right therapy at the right time.

Important Note Regarding Historical Dividend References

References in this press release to dividend yield, dividend history,

enterprise value, capital stewardship, shareholder value creation, or other historical performance metrics relate solely to Mr. Busch’s

prior service at Global Medical REIT, Inc., now Chiron Real Estate, Inc., and are provided only as biographical background regarding Mr.

Busch’s prior professional experience. Such references do not relate to Aditxt, Inc. and should not be understood as a statement,

projection, forecast, commitment, or indication that Aditxt intends to declare, pay, initiate, maintain, or recommend dividends or any

other distributions to stockholders.

Aditxt does not currently have a dividend policy and has no current

plan or intention to declare or pay cash dividends or other distributions to stockholders. Any future determination regarding dividends,

if ever considered, would be subject to the discretion and approval of Aditxt’s Board of Directors and would depend on, among other

things, Aditxt’s financial condition, operating results, capital requirements, liquidity, contractual restrictions, applicable law,

and other factors the Board may deem relevant. Investors should not infer from Mr. Busch’s prior experience at another public company

that Aditxt will adopt any similar dividend, capital allocation, financing, investor relations, or shareholder return strategy.

Forward-Looking Statements

This press release contains forward-looking

statements within the meaning of the Private Securities Litigation Reform Act of 1995 and other federal securities laws.

Forward-looking statements include all statements other than statements of historical fact, including, without limitation,

statements regarding Aditxt, Inc.’s expectations, plans, objectives, strategy, priorities, business outlook, leadership

transition, anticipated benefits of the appointment of Jeffrey M. Busch as Interim Chief Executive Officer, the expected impact of

Mr. Busch’s prior public company, healthcare, capital markets, operational, commercial, and strategic experience,

Aditxt’s ability to advance, commercialize, grow, finance, scale, or otherwise realize value from Ignite Proteomics or any of

Aditxt’s other businesses, assets, subsidiaries, platforms, technologies, products, services, intellectual property,

collaborations, clinical initiatives, regulatory strategies, reimbursement opportunities, market opportunities, investor relations

initiatives, capital markets activities, strategic partnerships, or other corporate objectives.

Forward-looking statements may include words such as “anticipate,”

“believe,” “continue,” “could,” “estimate,” “expect,” “intend,”

“may,” “plan,” “potential,” “pursue,” “seek,” “should,” “target,”

“will,” “would,” “accelerate,” “advance,” “build,” “commercialize,”

“expand,” “enhance,” “execute,” “grow,” “improve,” “lead,” “support,”

“transform,” and similar words, phrases, or expressions, although not all forward-looking statements contain these identifying

words.

These forward-looking statements include, but

are not limited to, statements regarding Aditxt’s expectations concerning its new leadership structure; the Company’s

ability to transition successfully following the appointment of a new Interim Chief Executive Officer; the ability of the new

Interim Chief Executive Officer to implement any strategic, operational, commercial, financing, investor relations, capital

allocation, or other initiatives; the Company’s ability to execute an accelerated commercialization strategy centered on

Ignite Proteomics; the potential clinical utility, commercial opportunity, market demand, reimbursement potential, revenue

potential, scalability, validation, adoption, or competitive position of Ignite’s precision oncology diagnostics platform,

including its Reverse Phase Protein Array technology; the Company’s ability to maintain, utilize, expand, or benefit from CLIA

certification, Medicare reimbursement, PLA coding, clinical collaborations, research partnerships, institutional relationships, or

other commercial or regulatory infrastructure; the Company’s ability to generate revenue, improve financial discipline,

satisfy obligations to employees, vendors, clinical partners, investors, creditors, or other stakeholders, or create or enhance

long-term stockholder value; and any statements concerning patients, partners, employees, investors, capital markets engagement,

commercial discipline, transparency, accountability, stakeholder responsibility, addressable market, clinical need, or future

growth.

Historical references in this press release to Mr. Busch’s prior

professional experience, including references to enterprise value, dividend yield, dividend programs, capital stewardship, shareholder

value, public company leadership, healthcare-sector experience, capital markets experience, or the performance, strategy, capital allocation,

financing, dividend history, investor relations, or stockholder return profile of any company with which Mr. Busch was previously affiliated,

are provided solely for biographical and background purposes. Such references are not predictions, projections, guarantees, or indications

of Aditxt’s future performance, strategy, financial results, stock price, market capitalization, enterprise value, capital allocation,

financing activities, investor relations activities, dividend policy, or stockholder returns. Aditxt does not currently have a dividend

policy and has no current plan or intention to declare or pay dividends or other distributions to stockholders. Any future dividend or

distribution, if ever considered, would be subject to the discretion and approval of Aditxt’s Board of Directors and would depend

on numerous factors, including Aditxt’s financial condition, operating results, liquidity, capital requirements, contractual restrictions,

applicable law, and other considerations the Board may deem relevant. Investors should not place undue reliance on historical biographical

information regarding Mr. Busch’s prior experience or infer that Aditxt will adopt, implement, or achieve similar results, dividend

practices, capital allocation strategies, financing strategies, or shareholder return outcomes.

Forward-looking statements are based on current expectations, estimates,

assumptions, beliefs, and information available to Aditxt as of the date of this press release. These statements are subject to significant

risks, uncertainties, and other factors, many of which are outside Aditxt’s control, that could cause actual results, performance,

achievements, events, or circumstances to differ materially from those expressed or implied by the forward-looking statements. These risks

and uncertainties include, among others, risks related to Aditxt’s liquidity, capital resources, ability to continue as a going

concern, ability to obtain additional financing on acceptable terms or at all, ability to satisfy existing and future obligations, ability

to maintain compliance with Nasdaq listing standards, ability to manage leadership transitions, ability to retain and motivate key personnel,

ability to execute its business strategy, ability to commercialize or generate revenue from Ignite Proteomics or any other business line,

ability to maintain regulatory, laboratory, reimbursement, clinical, commercial, vendor, employee, and strategic relationships, market

acceptance of its products and services, competition, intellectual property protection, regulatory developments, healthcare reimbursement,

clinical validation, operational execution, macroeconomic conditions, capital markets conditions, and other risks described in Aditxt’s

filings with the Securities and Exchange Commission, including Aditxt’s most recent Annual Report on Form 10-K, Quarterly Reports

on Form 10-Q, Current Reports on Form 8-K, and other SEC filings.

Forward-looking statements speak only as of the date they are made.

Aditxt undertakes no obligation to update, revise, or publicly release any update or revision to any forward-looking statement, whether

as a result of new information, future events, changes in expectations, or otherwise, except as required by law. Readers are cautioned

not to place undue reliance on any forward-looking statements.

Investor Relations

IR@aditxt.com

www.aditxt.com

###

XML — IDEA: XBRL DOCUMENT

XML

Filename: R1.htm · Sequence: 7

v3.26.1

Cover

May 29, 2026

Cover [Abstract]

Document Type

8-K

Amendment Flag

false

Document Period End Date

May 29, 2026

Entity File Number

001-39336

Entity Registrant Name

ADITXT, INC.

Entity Central Index Key

0001726711

Entity Tax Identification Number

82-3204328

Entity Incorporation, State or Country Code

Entity Address, Address Line One

2569 Wyandotte Street

Entity Address, Address Line Two

Suite 101

Entity Address, City or Town

Mountain View

Entity Address, State or Province

Entity Address, Postal Zip Code

94043

City Area Code

650

Local Phone Number

870-1200

Written Communications

false

Soliciting Material

false

Pre-commencement Tender Offer

false

Pre-commencement Issuer Tender Offer

false

Title of 12(b) Security

Common Stock, par value $0.001 per share

Trading Symbol

ADTX

Security Exchange Name

NASDAQ

Entity Emerging Growth Company

false

- Definition

Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.

+ References

No definition available.

+ Details

Name:

dei_AmendmentFlag

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Area code of city

+ References

No definition available.

+ Details

Name:

dei_CityAreaCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Cover page.

+ References

No definition available.

+ Details

Name:

dei_CoverAbstract

Namespace Prefix:

dei_

Data Type:

xbrli:stringItemType

Balance Type:

Period Type:

duration

- Definition

For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.

+ References

No definition available.

+ Details

Name:

dei_DocumentPeriodEndDate

Namespace Prefix:

dei_

Data Type:

xbrli:dateItemType

Balance Type:

Period Type:

duration

- Definition

The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.

+ References

No definition available.

+ Details

Name:

dei_DocumentType

Namespace Prefix:

dei_

Data Type:

dei:submissionTypeItemType

Balance Type:

Period Type:

duration

- Definition

Address Line 1 such as Attn, Building Name, Street Name

+ References

No definition available.

+ Details

Name:

dei_EntityAddressAddressLine1

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Address Line 2 such as Street or Suite number

+ References

No definition available.

+ Details

Name:

dei_EntityAddressAddressLine2

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the City or Town

+ References

No definition available.

+ Details

Name:

dei_EntityAddressCityOrTown

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Code for the postal or zip code

+ References

No definition available.

+ Details

Name:

dei_EntityAddressPostalZipCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the state or province.

+ References

No definition available.

+ Details

Name:

dei_EntityAddressStateOrProvince

Namespace Prefix:

dei_

Data Type:

dei:stateOrProvinceItemType

Balance Type:

Period Type:

duration

- Definition

A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityCentralIndexKey

Namespace Prefix:

dei_

Data Type:

dei:centralIndexKeyItemType

Balance Type:

Period Type:

duration

- Definition

Indicate if registrant meets the emerging growth company criteria.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityEmergingGrowthCompany

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.

+ References

No definition available.

+ Details

Name:

dei_EntityFileNumber

Namespace Prefix:

dei_

Data Type:

dei:fileNumberItemType

Balance Type:

Period Type:

duration

- Definition

Two-character EDGAR code representing the state or country of incorporation.

+ References

No definition available.

+ Details

Name:

dei_EntityIncorporationStateCountryCode

Namespace Prefix:

dei_

Data Type:

dei:edgarStateCountryItemType

Balance Type:

Period Type:

duration

- Definition

The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityRegistrantName

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityTaxIdentificationNumber

Namespace Prefix:

dei_

Data Type:

dei:employerIdItemType

Balance Type:

Period Type:

duration

- Definition

Local phone number for entity.

+ References

No definition available.

+ Details

Name:

dei_LocalPhoneNumber

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 13e

-Subsection 4c

+ Details

Name:

dei_PreCommencementIssuerTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14d

-Subsection 2b

+ Details

Name:

dei_PreCommencementTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Title of a 12(b) registered security.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b

+ Details

Name:

dei_Security12bTitle

Namespace Prefix:

dei_

Data Type:

dei:securityTitleItemType

Balance Type:

Period Type:

duration

- Definition

Name of the Exchange on which a security is registered.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection d1-1

+ Details

Name:

dei_SecurityExchangeName

Namespace Prefix:

dei_

Data Type:

dei:edgarExchangeCodeItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14a

-Subsection 12

+ Details

Name:

dei_SolicitingMaterial

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Trading symbol of an instrument as listed on an exchange.

+ References

No definition available.

+ Details

Name:

dei_TradingSymbol

Namespace Prefix:

dei_

Data Type:

dei:tradingSymbolItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Securities Act

-Number 230

-Section 425

+ Details

Name:

dei_WrittenCommunications

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration